Lucknow, Nov. 21 -- Molecular testing is emerging as a crucial tool to determine the most effective treatment and avoid unnecessary surgeries and chemotherapy for cancer treatment. Today doctors are testing DNA and other components to determine cancer incidence. Sanjay Gandhi PostGraduate Institute of Medical Sciences, pathology department head, Dr Vinita Agarwal said, "The shift from conventional morphology-based diagnosis to molecular cytopathology is the focus of discussions at Cytocon 2026, which began on Friday, where more than 800 experts have gathered to highlight the growing role of molecular markers in diagnosing and treating cancers of the thyroid, breast, cervix, lungs, ovaries and salivary glands." Hosted by the SGPGIMS, experts from 15 countries will deliberate the future of cytology for future generations over the next four days. Earlier, doctors primarily relied on the shape, size and arrangement of cells to determine whether a tumour was benign or malignant. Molecular testing now allows specialists to examine genetic alterations and specific markers in the same small samples obtained through needle aspiration....